Evidence map›Paper›PMID 29885741›Full record

ArticleSurgery2018

Readmission and resource utilization after orthotopic heart transplant versus ventricular assist device in the National Readmissions Database, 2010-2014.

Laith Mukdad, Aditya Mantha, Esteban Aguayo, Yas Sanaiha, Yen-Yi Juo, Boback Ziaeian, Richard J Shemin, Peyman Benharash

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Laith MukdadDivision of Cardiac Surgery, University of California Los Angeles.
Aditya ManthaDivision of Cardiac Surgery, University of California Los Angeles.
Esteban AguayoDivision of Cardiac Surgery, University of California Los Angeles.
Yas SanaihaDivision of Cardiac Surgery, University of California Los Angeles.
Yen-Yi JuoDivision of Cardiac Surgery, University of California Los Angeles.
Boback ZiaeianDivision of Cardiology, University of California Los Angeles.
Richard J SheminDivision of Cardiac Surgery, University of California Los Angeles.
Peyman BenharashDivision of Cardiac Surgery, University of California Los Angeles. Electronic address: PBenahrash@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

American Heart Association-American Stroke Association 17SDG33630113
6 · The paper itself

Abstract

backgroundAs the technology of ventricular assist devices continues to improve, the morbidity and mortality for patients with a ventricular assist device is expected to approach that of orthotopic heart transplantation. The present study was performed to compare perioperative outcomes, readmission, and resource utilization between ventricular assist device implantation and orthotopic heart transplantation, using a national cohort.

methodsPatients who underwent either orthotopic heart transplantation or ventricular assist device implantation from 2010 to 2014 in the National Readmission Database were selected.

resultsOf the 12,111 patients identified during the study period, 5,440 (45%) received orthotopic heart transplantation, while 6,671 (55%) received ventricular assist devices. Readmissions occurred frequently after ventricular assist device implantation and orthotopic heart transplantation, with greater rates at 30 days (29% versus 24%, P=.005) and 6 months (62% versus 46%, P < .001) for the ventricular assist device cohort. Cost of readmission was greater among ventricular assist device patients at 30 days ($29,115 versus $21,586, P=.0002) and 6 months ($34,878 versus $20,144, P = .0106).

conclusionReadmission rates and costs for patients with a ventricular assist device remain greater than their orthotopic heart transplantation counterparts. Given the projected increases in ventricular assist device utilization and limited transplant donor pool, further emphasis on cost containment and decreased readmissions for patients undergoing a ventricular assist device is essential to the viability of such therapy in the era of value-based health care delivery.

Indexed as

FemaleHealth Care CostsHeart-Assist DevicesHeart TransplantationHumansMaleMiddle AgedPatient ReadmissionPostoperative ComplicationsRetrospective StudiesUnited StatesUtilization Review

Identifiers

PMID29885741
PMCPMC7652384
OpenAlexW2806882004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.